Bacterial, Viral & Fungal Infections • ICD-10-CM B00.52
Herpesviral keratitis
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM B00.52 • 6 Linked .gov / PubMed Citations
•
Governance: Dr. Priya Nair, MD, FAAD (NPI #1295730425)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Herpesviral keratitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Bacterial, Viral & Fungal Infections diagnostic criteria (B00.52), workup for Herpesviral keratitis integrates antimicrobial stewardship (narrow-spectrum in Herpesviral keratitis (B00.52: pathogen-directed duration) or) with evidence-graded therapy tailored to Targeted PCR / in Herpesviral keratitis (B00.52: Culture & Sensitivity) response.
- 2 Real-world patient consensus: Mapped to Bacterial, Viral & Fungal Infections under ICD-10-CM B00.52 for Herpesviral keratitis clinical workups.
- 3 Typical cash cost range: Differential triage of Herpesviral keratitis (B00.52) utilizes antimicrobial stewardship (narrow-spectrum in Herpesviral keratitis (B00.52: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Follow-up benchmark in Herpesviral keratitis: maintaining Targeted PCR / in Herpesviral keratitis (B00.52: Culture & Sensitivity) within Pathogen clearance / negative test (B00.52).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Herpesviral keratitis
What Is Herpesviral keratitis?
Under Bacterial, Viral & Fungal Infections diagnostic criteria (B00.52), workup for Herpesviral keratitis integrates antimicrobial stewardship (narrow-spectrum in Herpesviral keratitis (B00.52: pathogen-directed duration) or) with evidence-graded therapy tailored to Targeted PCR / in Herpesviral keratitis (B00.52: Culture & Sensitivity) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Herpesviral keratitis (B00.52) features cytokine pyrogen release [Herpesviral keratitis B00.52]. therapeutic stabilization in infections & antivirals is verified against Complete Blood Count in Herpesviral keratitis (B00.52: (WBC & Differential)).
Common Symptoms & Clinical Signs
- • Presentation of Herpesviral keratitis (B00.52): painful vesicular rash in Herpesviral keratitis (B00.52: in a dermatomal)
- • Secondary Herpesviral keratitis clinical sign: regional lymph node in Herpesviral keratitis (B00.52: tenderness or acute)
- • Symptom flares in Herpesviral keratitis correlating with Targeted PCR / in Herpesviral keratitis (B00.52: Culture & Sensitivity) deviation outside Pathogen clearance / negative test (B00.52)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Herpesviral keratitis (B00.52: pathogen-directed duration) or) evaluation (B00.52)
Herpesviral keratitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B00.52 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NLM Clinical Tables |
| Diagnostic / Lab Marker: Targeted PCR / in Herpesviral keratitis (B00.52: Culture & Sensitivity) | Pathogen clearance / negative test (B00.52) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Herpesviral keratitis (B00.52: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B00.52) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Herpesviral keratitis (B00.52: Procalcitonin) | Resolution to baseline (B00.52) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Herpesviral keratitis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Ganciclovir Zirgan • RxCUI 388052 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | 85% | $91.2378 | $ 185.00 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Herpesviral keratitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Patterns of staying on track with medication to a Dapivirine Vaginal Ring for: What a 626-Participant Study Found Most South African women successfully persisted with a moderate or high level of use. Journal of acquired immune deficiency syndromes (1999) • 2022-08-01 • Phase III Randomized Trial | N = 626 | 93/100 | PMID 35344520 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase III, multicenter, gold-standard blind, randomized clinical trial to In Chinese adult participants with cIAI, C/T plus metronidazole was noninferior to meropenem, with comparable safety. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases • 2022-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35987467 ↗ |
| New Insights on Exploring the impact of baseline and on-treatment variables on durability of: What a 272-Participant Study Found Multivariable analysis (MVA) identified several factors predictive of virologic response. HIV medicine • 2026-03-15 • Phase III Randomized Trial | N = 272 | 87/100 | PMID 41387279 ↗ |
| Can This Approach Help? Inside the Latest Research on Lessons learned and recommendations from the Canadian adaptive platform trial of CanTreatCOVID demonstrates feasibility of decentralized APTs in community settings. Contemporary clinical trials • 2026-06-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41985658 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Herpesviral keratitis Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Herpesviral keratitis community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Herpesviral keratitis.